Compass Therapeutics
71 articles about Compass Therapeutics
-
Compass Therapeutics Announces Presentation on CTX-8371, A Bispecific Antibody Targeting PD-1 and PD-L1, at the 2022 AACR Annual Meeting in New Orleans
3/30/2022
Compass Therapeutics Inc. announced today that it will present preclinical data on CTX-8371, a next generation bispecific checkpoint inhibitor that simultaneously targets PD-1 and PD-L1 at the upcoming American Association for Cancer Research (AACR) Annual Meeting, which is being held April 8-13, 2022.
-
Compass Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update
3/21/2022
Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today reported fourth quarter and full year 2021 financial results and provided a corporate update.
-
Compass Therapeutics Announces US FDA Clearance of Investigational New Drug Application for a Phase 2 Study of CTX-009, a Bispecific Antibody That Simultaneously Targets Delta-like Ligand 4 and Vascular Endothelial Growth Factor A (VEGF-A)
1/20/2022
Compass Therapeutics, Inc. announced that the U.S. Food and Drug Administration has cleared its IND application for CTX-009, enabling the company to initiate a global Phase 2 clinical trial for CTX-009 in patients who have advanced Biliary Tract Cancers in the United States and South Korea.
-
Compass Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference
1/7/2022
Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage biopharmaceutical company developing proprietary antibody-based therapeutics to treat cancer, today announced that Thomas Schuetz, M.D., Ph.D., Co-founder and Chief Executive Officer, will present a company update at the 40th Annual J.P. Morgan Healthcare Conference on Wednesday, January 12, 2022.
-
Compass Therapeutics to Present at the Piper Sandler 33rd Annual Healthcare Conference
11/22/2021
Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage biopharmaceutical company developing proprietary antibody-based therapeutics to treat cancer, today announced Thomas J. Schuetz, MD, PhD, Co-founder, and Chief Executive Officer is presenting at the Piper Sandler 33rd Annual Healthcare Conference to be held virtually November 29, 2021 to December 2, 2021.
-
Compass Therapeutics Reports Third Quarter 2021 Financial Results and Provides Corporate Update
11/12/2021
Compass Therapeutics, Inc. today reported financial results for the third quarter ended September 30, 2021 and highlighted recent corporate accomplishments.
-
Compass Therapeutics Announces Pricing of Approximately $125 Million Public Offering of Common Stock and Uplisting to Nasdaq Capital Market
11/2/2021
Compass Therapeutics, Inc., a clinical-stage biopharmaceutical company developing proprietary antibody-based therapeutics to treat cancer, announced that it has priced an underwritten public offering to sell 35,715,000 shares of common stock at a public offering price of $3.50 per share.
-
Compass Therapeutics Announces Proposed Public Offering of Common Stock and Uplisting to Nasdaq Capital Market - Nov 01, 2021
11/1/2021
Compass Therapeutics, Inc., a clinical stage biopharmaceutical company developing proprietary antibody-based therapeutics to treat cancer, announced that it intends to offer and sell shares of common stock in an underwritten public offering.
-
Compass Reports the Advancement of CTX-009, a Bispecific Antibody, to Phase 2a Development in Patients with Biliary Tract Cancers (BTC), and the Clearance of a Key Clinical Hurdle
11/1/2021
Compass Therapeutics, Inc. provided an update on the clinical development of CTX-009, a dual anti-angiogenic bispecific antibody targeting DLL4 and VEGF-A.
-
CTX-009 (ABL001/ES104) Clinical Data Presented Today at the New Drugs on the Horizon Plenary Session of the 2021 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
10/8/2021
Compass Therapeutics, Inc. (OTC:CMPX) and ABL Bio (KOSDAQ: 298380) presented today clinical trial data for CTX-009 (ABL001/ES104), a dual anti-angiogenic bispecific antibody targeting DLL4 and VEGF-A, at an oral plenary session during the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics.
-
Compass Therapeutics and ABL Bio Announce Presentation of CTX-009 Clinical Data as a Plenary Session of the 2021 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
10/1/2021
Compass Therapeutics, Inc. and ABL Bio, Inc. announced today that the Phase 1 monotherapy dose escalation and expansion study data for CTX-009 (ABL001/ES104), a bispecific dual angiogenesis inhibitor targeting DLL4 and VEGF-A, has been selected for an oral plenary presentation at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, being held virtually on October 7-10, 2021.
-
Compass Therapeutics to Present at the Citi 16th Annual Biopharma Virtual Conference
8/13/2021
Compass Therapeutics, Inc., a clinical-stage biotechnology company developing proprietary antibody therapeutics announced that Thomas Schuetz, MD, PhD, Co-Founder and Chief Executive Officer will participate in a fireside chat at the Citi 16th Annual Biopharma Conference.
-
Compass Therapeutics, Inc. to Acquire TRIGR Therapeutics, Inc.
5/13/2021
Compass Therapeutics, Inc. (“Compass”; OTCQB: CMPX), a clinical-stage biotechnology company developing proprietary antibody therapeutics to treat cancer, and TRIGR Therapeutics, Inc. (“TRIGR”), a private biotechnology oncology company, today announced that the companies have entered into a definitive merger agreement, under which Compass, through a subsidiary, will acquire TRIGR,
-
Compass Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update
3/5/2021
Compass Therapeutics, Inc. (OTCQB: CMPX), a clinical-stage biotechnology company developing proprietary antibody therapeutics intended to engage the immune system to treat both solid tumors and hematological malignancies, today reported fourth quarter and full year 2020 financial results and provided a business update.
-
Compass Therapeutics Announces Participation in March 2021 Investor Conferences
3/4/2021
Compass Therapeutics, Inc. (OTCQB: CMPX), a clinical-stage biotechnology company developing proprietary antibody therapeutics intended to engage the immune system to treat both solid tumors and hematological malignancies, today announced that Thomas Schuetz, MD, PhD, Co-Founder and Chief Executive Officer of Compass Therapeutics, will participate in the following virtual investor conferences:
-
Compass Therapeutics, Inc. Provides Corporate Update
9/15/2020
Compass Therapeutics, Inc. , a clinical-stage biotechnology company developing proprietary antibody therapeutics intended to engage the immune system to treat both solid tumors and hematological malignancies, today announced the promotion of Vered Bisker-Leib, PhD, MBA to President, in addition to her current position as Chief Operating Officer, and the appointment of Brett Kaplan, MD to its Board of Directors and
-
Compass Therapeutics Announces Publication in the Journal Science of Preclinical Data Supporting the Potential of CTX-2026, a Novel Antibody to the Butyrophilin BTN3A1, in Ovarian Cancer Tumor Models
8/24/2020
Compass Therapeutics Announces Publication in the Journal Science of Preclinical Data Supporting the Potential of CTX-2026, a Novel Antibody to the Butyrophilin BTN3A1, in Ovarian Cancer Tumor Models Data Demonstrate Overexpression of BTN3A1 is Associated with a Poor Prognosis in Ovarian Cancer and the Ability of CTX-2026 to Engage both Gamma Delta and Alpha Beta T Cells to Overcome the Immunosuppressive Tumor Microenvironment CAMBRIDGE, Mass.--( BUS
-
Compass Therapeutics Completes Reverse Merger and Closes $60 Million Private Placement
6/23/2020
Compass Therapeutics, a clinical-stage biotechnology company developing proprietary antibody therapeutics intended to engage the immune system to treat both solid tumors and hematological malignancies, today announced the closing of a $60 million private placement financing and the completion of a reverse merger transaction with Olivia Ventures, Inc.
-
Compass Therapeutics Announces Publication of Data Demonstrating the Preclinical Efficacy and Safety of CTX-471, a Unique Fully Human Agonist of CD137
3/30/2020
Compass Therapeutics announced the publication of extensive data demonstrating the preclinical efficacy and safety of the company’s lead investigational therapy, CTX-471, which is currently being evaluated in a Phase 1 clinical trial.
-
Compass Therapeutics to Present at the 40th Cowen Health Care Conference
2/28/2020
Compass Therapeutics, a clinical-stage biotechnology company targeting the human immune synapse with a new generation of monoclonal and multispecific antibody therapeutics, today announced that Thomas Schuetz, M.D., Ph.D., co-founder and chief executive officer, will present a company overview at the 40th Annual Cowen Health Care Conference in Boston on Tuesday, March 3, 2020.